← Leaderboards
Fatmata Sesay
Virginia Commonwealth University
$111,940
Attributed
$111,940
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $39.5K · FY2019–21$50K$37.5K$25K$12.5K$0
'19
'20
'21
Funding mix
By agency
NIH$111,940 · 1
By mechanism
F31$111,940 · 1
Top collaborators
No co-investigators on record.
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Larisa Litovchick$3,327,925
- Yue Sun$2,061,283
- Audra Iness$116,641
- Evan G Buettmann$224,252
Others in their field
Other Emerging Leaders on “Agreement”
- Peter K Fritschel · California Institute Of Technology$78,820,000
- Jerene Shaheed · Administrative Resource Center, Treasury Franchise Services$77,493,783
- Julie Ake · National Institute Of Allergy And Infectious Diseases$50,742,120
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$46,590,142
- Claudia Valmonte · The Emmes Company, Llc$38,115,589
- Wendy Sammons-Jackson · National Institute Of Allergy And Infectious Diseases$29,269,420
Research focus
AgreementBaseBioluminescence ImagingCancer CellCancer Cell LineCdk4 GeneCell LineCell ProliferationCellsComplexCyclin-Dependent Kinase Inhibitor 2aDiagnosisDoseDown-RegulationEmbryonic DevelopmentEpithelial Ovarian CancerExperimental ModelsFunctional StatusFutureG1/S Checkpoint PathwayGenesGeneticGenetic TranscriptionAdult
Grant awards (3)
The relative impact of the Hippo and RB tumor suppressor pathways inhibition on the ovarian cancer progression$39,492
F31 · FY2021 · CA · contact PI
The relative impact of the Hippo and RB tumor suppressor pathways inhibition on the ovarian cancer progression$36,476
F31 · FY2020 · CA · contact PI
The relative impact of the Hippo and RB tumor suppressor pathways inhibition on the ovarian cancer progression$35,972
F31 · FY2019 · CA · contact PI